ESLA News
Estrella Immunopharma Names Cynthia Pussinen CEO, Succeeding Cheng Liu
(RTTNews) - Monday, Estrella Immunopharma (ESLA), a clinical-stage biopharmaceutical company for treating cancer and autoimmune diseases, appointed Cynthia Pussinen as the Chief Executive Officer and Board Chair, effective October 25, 2026. She succeeds Cheng Liu, who will become...
Nasdaq News: Markets
Estrella Immunopharma Names Cynthia Pussinen CEO, Succeeding Cheng Liu
(RTTNews) - Monday, Estrella Immunopharma (ESLA), a clinical-stage biopharmaceutical company for treating cancer and autoimmune diseases, appointed Cynthia Pussinen as the Chief Executive Officer and Board Chair, effective October 25, 2026. She succeeds Cheng Liu, who will become...
Nasdaq News: Markets
Estrella Immunopharma, Inc. (NASDAQ: ESLA) (Estrella or the Company), a clinical-stage biopharmaceutical company developing next-generation ARTEMIS T-cell therapies for the treatment of cancer and autoimmune diseases, today announced the appointment of Cynthia Pussinen as Chief Executive Officer...
Business Wire
Estrella Immunopharma shares climbed 17.91% after hours following an update on its EB103 cancer therapy trial and early safety results.read more...
Benzinga
Estrella Immunopharma, Inc. (NASDAQ: ESLA) (Estrella or the Company), a clinical-stage biopharmaceutical company developing CD19- and CD22-targeted ARTEMIS T-cell therapies to treat cancers and autoimmune diseases, today announced that the first patient who received two infusions, each at 5 10...
Business Wire
The following developments are worth watching, with Dermata Therapeutics (NASDAQ:DRMA), Verastem (NASDAQ:VSTM), NeOnc Technologies Holdings (NASDAQ:NTHI), Netcapital (NASDAQ:NCPL), Iambic Therapeutics (NASDAQ:IAM) and Estrella Immunopharma (NASDAQ:ESLA) advancing distinct strategies.
24-7 Market News
Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) (Estrella or the Company), a clinical-stage biopharmaceutical company developing CD19- and CD22-targeted ARTEMIS T-cell therapies to treat cancers and autoimmune diseases, today announced the activation of a fifth clinical site for its ongoing...
Business Wire
Estrella Immunopharma, Inc. (NASDAQ: ESLA) (Estrella or the Company), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies to treat cancer and autoimmune diseases, today announced the activation of a fourth clinical site for its ongoing STARLIGHT-1...
Business Wire
Gainers
Bluejay Diagnostics (NASDAQ:BJDX) shares moved upwards by 43.0% to $1.43 during Wednesday's pre-market session. The company's market cap stands at $1.0 million.
Estrella Immunopharma (NASDAQ:ESLA)read more...
Benzinga
Estrella Immunopharma, Inc. (NASDAQ: ESLA) (Estrella or the Company), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies to treat cancer and autoimmune diseases, today announced the activation of a third clinical site for its ongoing STARLIGHT-1...
Business Wire
Estrella Immunopharma, Inc. (NASDAQ: ESLA) (Estrella or the Company), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies to treat cancer and autoimmune diseases, today announced the activation of a second clinical site for its ongoing STARLIGHT-1...
Business Wire